Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287573 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 488
- Enrollment target
NCT00287573 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 488 participants.
The verdict
NCT00287573, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 488 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System as compared to brachytherapy in patients experiencing in-stent restenosis.
Interventions
- DEVICE TAXUS Express2
- PROCEDURE Brachytherapy (beta source)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287573
The ClinicalTrials.gov registry entry for NCT00287573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAXUS Express2 is the first listed.
NCT00287573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287573 about?
NCT00287573 is a clinical study titled "Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis". The objective of this study is to evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System as compared to brachytherapy in patients experiencing in-stent restenosis.
What is the current status of trial NCT00287573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 488 participants. The study started on 2003-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00287573?
The interventions under investigation include: TAXUS Express2 (DEVICE), Brachytherapy (beta source) (PROCEDURE).
Who is sponsoring clinical trial NCT00287573?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.